List of Sernivo drug patents

Sernivo is owned by Primus Pharms.

Sernivo contains Betamethasone Dipropionate.

Sernivo has a total of 7 drug patents out of which 0 drug patents have expired.

Sernivo was authorised for market use on 05 February, 2016.

Sernivo is available in spray;topical dosage forms.

Sernivo can be used as treatment of plaque psoriasis.

The generics of Sernivo are possible to be released after 31 August, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9775851 PRIMUS PHARMS Topical formulations comprising a steroid
Aug, 2030

(7 years from now)

US9364485 PRIMUS PHARMS Topical formulations comprising a steroid
Aug, 2030

(7 years from now)

US9655907 PRIMUS PHARMS Topical formulations comprising a steroid
Aug, 2030

(7 years from now)

US10179137 PRIMUS PHARMS Topical formulations comprising a steroid
Aug, 2030

(7 years from now)

US9433630 PRIMUS PHARMS Topical formulations comprising a steroid
Aug, 2030

(7 years from now)

US9877974 PRIMUS PHARMS Topical formulations comprising a steroid
Aug, 2030

(7 years from now)

US9439911 PRIMUS PHARMS Topical formulations comprising a steroid
Aug, 2030

(7 years from now)

Drugs and Companies using BETAMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 05 February, 2016

Treatment: Treatment of plaque psoriasis

Dosage: SPRAY;TOPICAL

How can I launch a generic of SERNIVO before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in